CLDI: Calidi Bio P/S Multiple

Symbol and logo of brand Calidi Bio (CLDI)

High biomaterial costs and the risk of secondary offerings are putting pressure on Calidi Biotherapeutics (CLDI) share prices. The price-to-sales ratio trend visualizes these fluctuations, where forms the current metric value. A lack of operating cash flow coupled with inertial capital is hindering growth, yet the company's status as an innovator in stem cell drug delivery strengthens the authority of Calidi Biotherapeutics (CLDI) in the fight against oncology.

Calidi Bio - CLDI P/S Multiple (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for Calidi Biotherapeutics (CLDI)

- market price and analyst price targets:
Stock Quotes calidibio.com|CLDI - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Calidi Bio|CLDI - Total Company Value
- balance sheet equity data:
Net Assets per Single Share Calidi Biotherapeutics|CLDI - Book Capitalization|Market Capitalization to Book Value calidibio.com|CLDI - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Calidi Biotherapeutics|CLDI - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient calidibio.com|CLDI - Company Total Debt|Debt to Net Assets Ratio Calidi Bio|CLDI - Company Long-Term Debts|Company Short-Term Debt Calidi Biotherapeutics|Interim Coverage Ratio calidibio.com
- financial results and valuation multiples details:
CLDI - Company Net Income|Expected Net Profit Calidi Biotherapeutics|CLDI - Price to Earnings Ratio|Market Cap to Future Earnings Ratio calidibio.com|CLDI - PEG Multiple|Business Value to Operating Income Before Depreciation Calidi Bio|CLDI - Operating profit EBITDA|Net earnings per one share for the last twelve months Calidi Biotherapeutics|CLDI - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months calidibio.com|CLDI - Earnings growth in current year|Earnings growth forecast for next year Calidi Biotherapeutics
- issuer revenue and sales details:
CLDI - Company Revenue|Company Expected Revenue calidibio.com|CLDI - P/S Multiple|Market Cap to Future Revenue Ratio Calidi Bio
Summary company analytics:Calidi Biotherapeutics Inc., CLDI
Manufactured products of Calidi Biotherapeutics Inc.

The P/S ratio compares a business's market value to its annual revenue, allowing for an assessment of the premium paid per unit of generated income. For Calidi Biotherapeutics (CLDI), which focuses on costly oncology research without stable sales, this metric serves as an indicator of speculative expectations, making the price-to-sales multiple a critical marker of capital overvaluation risk.

Competing companies

Market Cap to Revenue beigene.com ONC|P/S Multiple HALO (Halozyme)|P/S Multiple Revolution Medicines Inc RVMD|AAPG - Price-to-Revenue Ratio|CGON: Price-to-Revenue Ratio|URGN: P/S Multiple|BCAX - Price-to-Revenue Coefficient|PSNL (Personalis) - P/S Multiple|Market Cap to Revenue Ratio ERAS (Erasca Inc)|P/S Multiple DCTH|Price-to-Revenue Coefficient Y-mAbs Corp|Aura Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CADL|Accuray - P/S Multiple|SLS: Price-to-Revenue Ratio|ACTU: P/S Multiple|CTOR - Price-to-Revenue Coefficient|Price-to-Revenue Ratio TuHURA Biosciences Inc.|Price to Sales protaratx.com TARA|Market Cap to Revenue FATE (Fate Therapeutics)|Market Cap to Sales Volume WHWK|P/S Multiple TCRX (TScan Therapeutics, Inc.)|Market Capitalization-to-Revenue Ratio CSBR|XBiotech USA - P/S Multiple|Price to Sales CEL-SCI Corporation|OS Therapies (OSTX) - Price-to-Revenue Ratio|radiopharmtheranostics.com - Market Capitalization-to-Revenue Ratio|ARTV (Artiva Biotherapeutics Inc.) - P/S Multiple|P/S Multiple Adlai Nortye Limited|Price-to-Revenue Ratio Veru Inc. (VERU)|TPST: Price-to-Sales Ratio|P/S Multiple XLO (Xilio Therapeutics)|Renovaro Biosciences (RENB) - Price to Sales|MURA: Market Cap to Revenue|KAPA - P/S Multiple|OKUR (onkuretherapeutics.com) - Market Cap to Revenue|GDTC: Market Cap to Sales Volume|CRIS (Curis Inc.) - P/S Multiple|Apollomics Corp (APLM) - Price-to-Revenue Coefficient|P/S Multiple THAR|Market Cap to Revenue advanbiomed.com ADVB|Price-to-Revenue Ratio Genprex, Inc. GNPX|Price-to-Revenue Coefficient sunshinebiopharma.com (SBFM)|Xenetic Bio - P/S Multiple|Salarius Pharmaceuticals Inc (SLRX) - Market Cap to Revenue|Purple Biotech Corp (PPBT) - Price-to-Revenue Ratio|AONC (American Oncology Network, Inc.) - Price-to-Revenue Ratio|BGNE (BeiGene, Ltd.) - P/S Multiple|Market Cap to Revenue Ratio CKPT (checkpointtx.com)|P/S Multiple ELEV|Price-to-Revenue Coefficient icadmed.com|P/S Multiple IKNA (Ikena Oncology)|NTBL - Market Cap to Revenue|Viracta - P/S Multiple|MOR - P/S Multiple|NAYA Biosciences Inc. (NAYA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio AAPGV